Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Pharmacotherapy|January 1, 1990
Prospective surveillance of intravenous amphotericin B use patternsT H Grasela, S D Goodwin, M K Walawander, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1994
Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infectionS D Goodwin, H A Gallis, A T Chow, et al.
The Annals of Pharmacotherapy|February 1, 1994
Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazoleT H Grasela, M T Pasko, S D Goodwin, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapyC V Fletcher, R C Brundage, R P Remmel, et al.
AIDS (London, England)|November 4, 2000
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected personsC V Fletcher, S P Kawle, T N Kakuda, et al.
The Journal of Infectious Diseases|November 9, 2000
Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected childrenS A Spector, K Hsia, F H Yong, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1994
Foscarnet for suppression of human immunodeficiency virus replicationC V Fletcher, A C Collier, F S Rhame, et al.
Pediatrics|June 1, 1996
Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effectsM W Kline, C V Fletcher, M E Federici, et al.
Clinical Pharmacology and Therapeutics|June 29, 2007
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patientsJ J Kiser, M L Carten, C L Aquilante, et al.
Clinical Pharmacology and Therapeutics|October 3, 1998
Concentration-controlled zidovudine therapyC V Fletcher, E P Acosta, K Henry, et al.
Pageof 8